Seiden, Michael V <br/><br/>
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.  [electronic resource] 

 -  Gynecologic oncology  Apr 2006 
 - 55-61 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0090-8258 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2005.09.036  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Alkylating--adverse effects<br/>Cohort Studies<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Organoplatinum Compounds--pharmacology<br/>Ovarian Neoplasms--drug therapy<br/>Sesquiterpenes--adverse effects